Loratadine: Nursing Drug Guide, Anaphylaxis Escalation & NCLEX Review

Loratadine is a selective peripheral H₁-receptor antagonist available as tablets, orally disintegrating tablets, and syrup. This guide reflects current U.S. OTC drug facts and Health Canada product monograph data for oral products.

• Tablets: Claritin; Clarityn; Alavert; multiple generic 10 mg strengths
• Combination products: Claritin-D and other loratadine/pseudoephedrine products — not interchangeable with loratadine alone
• Related agents: cetirizine and diphenhydramine — different sedation and emergency-use profiles
• Active metabolite: Desloratadine (Clarinex) — separate product; do not double-count without pharmacy review

Per U.S. OTC loratadine tablet labeling and Health Canada monograph:

• OTC (U.S.): Temporary relief of hay fever or upper respiratory allergy symptoms — runny nose, sneezing, itchy/watery eyes, itchy nose or throat
• Health Canada monograph: Seasonal and perennial allergic rhinitis; chronic urticaria and other allergic dermatologic disorders

Nurses use loratadine for nasal congestion (adjunct), rhinorrhea, pruritus, and hives. It does not replace epinephrine or emergency therapy for systemic allergic reactions.

Loratadine is a long-acting, selective peripheral H₁-receptor antagonist with minimal sedative activity in many adults at labeled doses. Metabolism occurs primarily in the liver via CYP3A4 and, to a lesser extent, CYP2D6, to the active metabolite descarboethoxyloratadine.

OTC labeling markets many products as non-drowsy; however, sedation, fatigue, and headache still occur in clinical trials and postmarketing reports. Taking more than the directed dose may increase drowsiness per U.S. OTC warnings.

Oral route only. Match tablet strength and formulation to the order and product label.

U.S. OTC tablets (10 mg)

↔On a small screen, swipe or scroll sideways to see the full table.

Severe hepatic impairment (Health Canada monograph)

U.S. OTC labeling does not print the hepatic table—nurses in acute care should use prescriber orders and pharmacy review when liver disease is documented.

• Absorption: Rapid; antihistaminic effect begins within 1–3 hours with duration about 24 hours at labeled doses per monograph
• Metabolism: Hepatic via CYP3A4 and CYP2D6; AUC and C_max approximately double in chronic alcoholic liver disease in monograph data
• Half-life: Mean elimination half-life for loratadine and active metabolite prolonged with increasing liver disease severity
• Elimination: Renal and fecal routes; not cleared appreciably by hemodialysis per monograph
• Skin testing: Discontinue about 48 hours before allergy skin testing per monograph — antihistamines may blunt wheal responses

Answer these before the first dose or when reconciling home supply:

• Correct patient, drug, strength (10 mg), route (oral), and scheduled time
• Clinical picture: Is this routine allergic rhinitis/urticaria—or systemic reaction needing emergency pathway (not oral antihistamine alone)?
• Only one antihistamine on MAR and home list (loratadine vs cetirizine, diphenhydramine, intranasal agents, etc.) via medication reconciliation
• Total loratadine in last 24 hours — OTC max one 10 mg tablet unless prescriber ordered otherwise
• Hepatic function — review history and labs when severe liver disease is documented; verify adjusted dose
• Renal function — OTC labeling says ask a doctor for kidney disease; review basic metabolic panel when clinically indicated
• New CYP3A4/CYP2D6 inhibitors (e.g., ketoconazole, erythromycin, cimetidine) — increased plasma concentrations reported in trials
• Hypersensitivity to loratadine or formulation excipients (e.g., lactose in some tablets)
• Pregnancy or breastfeeding — OTC: ask health professional; monograph not recommended unless benefit outweighs risk

• Known hypersensitivity to loratadine or any ingredient in the formulation (U.S. OTC and Health Canada monograph)

U.S. OTC labeling: do not use if you have ever had an allergic reaction to this product or any of its ingredients. Stop use and ask a doctor if an allergic reaction to this product occurs; seek medical help right away.

↔On a small screen, swipe or scroll sideways to see the full table.

• Oral administration with or without food per product label
• ODT or syrup: follow product-specific label for dissolving or measuring
• Document exact strength, time, and total daily dose from all sources (unit dose + patient-owned OTC Claritin)

• Reduced sneezing, rhinorrhea, nasal/ocular itching, and urticaria pruritus over hours
• 24-hour symptom control at labeled once-daily dosing when a single agent is used
• If inadequate response, prescriber may change agent or add non-antihistamine therapy — not by unsupervised double-dosing or stacking another antihistamine

• Anaphylaxis or systemic allergic reaction (angioedema, bronchospasm, hypotension, hoarse voice) — stop drug; treat per emergency pathway with epinephrine as ordered, not loratadine alone
• Allergic reaction to loratadine itself — U.S. OTC: stop use and seek medical help right away
• Marked somnolence after exceeding directed dose or stacking antihistamines
• Palpitations or tachycardia — rare postmarketing reports per monograph
• Signs of abnormal hepatic function (jaundice, dark urine) — abnormal hepatic function reported rarely
• Allergic rash that worsens or spreads with systemic symptoms — reassess for drug reaction versus treated urticaria

Common adverse reactions per product monograph and trials:

↔On a small screen, swipe or scroll sideways to see the full table.

Postmarketing (rare): alopecia, anaphylaxis, abnormal hepatic function, palpitations, tachycardia. Convulsions reported very rarely. Report per facility policy.

Health Canada monograph: overdoses have caused somnolence, tachycardia, and headache. A single acute ingestion of 160 mg produced no adverse effects in reported data. U.S. OTC labeling directs contacting poison control for overdose.

Antidote

No specific antidote is described in the reviewed prescribing information. Treatment is symptomatic and supportive (activated charcoal, gastric lavage per clinical judgment). Loratadine is not cleared appreciably by hemodialysis per monograph.

• Loratadine vs desloratadine (Clarinex) — related active metabolite; different products and doses
• Claritin vs Claritin-D — D product contains pseudoephedrine; not interchangeable
• Loratadine vs cetirizine vs fexofenadine — verify generic name on MAR; patients may not know they are duplicate antihistamines
• Hospital formulary vs home Claritin bottle — duplicate dosing when both are available
• Sound-alike orders: verbal “Claritin” confused with other agents — read back generic name and strength

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Allergy symptom relief versus baseline (rhinitis, urticaria, pruritus)
• Level of sedation, especially after duplicate dosing or exceeding directed dose
• Signs of systemic allergic reaction after first doses or new allergen exposure
• Hepatic function trend when liver disease is documented
• Heart rate if palpitations reported (rare)

Document

• Dose, strength, time, route, and 24-hour total from all sources
• Home OTC reconciliation and duplicate-antihistamine counseling
• Hepatic dose verification when liver disease or rising transaminases are present
• Escalation to emergency care if anaphylaxis signs appeared instead of routine antihistamine response

• Take only as directed — no more than one 10 mg OTC tablet in 24 hours unless prescriber says otherwise; taking more may cause drowsiness
• Loratadine helps allergy symptoms but does not replace an epinephrine auto-injector or emergency care for severe reactions
• Do not combine with other allergy antihistamines unless the prescriber directs
• Bring all allergy bottles to appointments (Claritin = loratadine)
• Seek urgent care for throat swelling, trouble breathing, hoarse voice, or widespread rash with dizziness
• Liver or kidney problems, pregnancy, or breastfeeding — talk with prescriber before starting OTC product
• Keep tablets and syrup out of reach of children — overdose causes serious effects in young children

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for loratadine using a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (anaphylaxis escalation, duplicate antihistamine dosing, and hepatic dose safety).

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.